M&A Deal Summary

Arresto Biosciences Acquires Aeon Bioscience

On December 20, 2010, Arresto Biosciences acquired life science company Aeon Bioscience from Greer Capital Advisors for 255M USD

Acquisition Highlights
  • This is Arresto Biosciences’ 1st transaction in the Life Science sector.
  • This is Arresto Biosciences’ largest (disclosed) transaction.
  • This is Arresto Biosciences’ 1st transaction in the United States.
  • This is Arresto Biosciences’ 1st transaction in Alabama.

M&A Deal Summary
Date 2010-12-20
Target Aeon Bioscience
Sector Life Science
Buyer(s) Arresto Biosciences
Sellers(s) Greer Capital Advisors
Deal Type Add-on Acquisition
Deal Value 255M USD

Target

Aeon Bioscience

Birmingham, Alabama, United States
Aeon Bioscience, Inc. is a developer of a drug-eluting stent, to overcome the current concerns of late stent thrombosis, or blood clot formation at or near the site of the stent and vessel closure due to formation of scar tissue, known as restenosis. Aeon Bioscience was founded in 2007 and is based in Birmingham, Alabama.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Arresto Biosciences

Palo Alto, California, United States
Category Company
Founded 2007
Sector Life Science
DESCRIPTION

Arresto Biosciences is a biotechnology company that develops medicines to treat fibrotic diseases and cancer by targeting enzymes involved in the synthesis of the extracellular matrix. In addition to AB0024, the company has preclinical candidates targeting proteins associated with various inflammatory diseases. The company is headquartered in Palo Alto, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Alabama) 1 of 1
Country (United States) 1 of 1
Year (2010) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Greer Capital Advisors

Mountain Brook, Alabama, United States

Investor

Category Private Equity Firm
Founded 2002
Size Small
Type Sector Focused
DESCRIPTION

Greer Capital Advisors (GCA) is a specialized, heathcare focused private equity firm that targets investments in Alabama based companies. Within healthcare, GCA looks for companies in the pharmaceutical, biotechnology, medical device, and diagnostics industries. GCA prefers early and growth stage investments and generally seeks to invest between $1 to $2 million per transaction. Greer Capital Advisors was formed in 2002 and is based in Birmingham, Alabama.

DEAL STATS #
Overall 5 of 13
Sector (Life Science) 4 of 10
Type (Add-on Acquisition) 4 of 10
State (Alabama) 2 of 7
Country (United States) 5 of 13
Year (2010) 1 of 2
Size (of disclosed) 2 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-10-08 BioDtech

Birmingham, Alabama, United States

BioDtech, Inc. develops and markets products for the detection, neutralization, and removal of biological toxins for pharmaceutical manufacturing and clinical applications. BioDtech was founded in 2003 and is based in Birmingham, Alabama.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-12-23 Atherotech

Birmingham, Alabama, United States

Atherotech is a clinical reference laboratory specializing in diagnostic testing for cardio-metabolic disease. The Company’s proprietary “VAP” test allows physicians to identify at-risk patients through a variety of cholesterol and lipid bio-markers with much greater accuracy and at significantly lower cost to the health care system than competitive testing products. The company’s state-of-the-art central laboratory processes millions of tests annually.

Sell -
Mergr

Product

Company

Legal